Payment overview · 2025
General Payments
$34,428.01
91 reported records · 8 companies
Healthcare provider profile · identity verified
Nathan L Bennett, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · PITTSBURGH, PA · NPI 1992775548
Verified facts
What the public records show
CMS Open Payments records show Nathan L Bennett, M.D. received $34,428.01 in general payments during 2025 across 91 reported records.
ABBVIE INC. accounted for 73.9% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 12 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Botox, Nurtec Odt, Qulipta.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BOTOX as an associated drug or biological on 140321 records involving 30103 distinct recipient NPIs. Public Medicare Part D data also shows 33 claims for Botox by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported QULIPTA as an associated drug or biological on 298617 records involving 58957 distinct recipient NPIs. Public Medicare Part D data also shows 38 claims for Qulipta by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Synthroid by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 37 claims for Ozempic by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Rybelsus as an associated drug or biological on 161257 records involving 55409 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Rybelsus by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 61 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported NURTEC ODT as an associated drug or biological on 217574 records involving 54025 distinct recipient NPIs. Public Medicare Part D data also shows 24 claims for Nurtec Odt by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| ABBVIE INC. | Unresolved — no canonical attribution shown | $25,435.18 | 73.9% | 49 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $6,156.50 | 17.9% | 23 | 2025 |
| Axsome Therapeutics, Inc. | Unresolved — no canonical attribution shown | $2,065.69 | 6.0% | 3 | 2025 |
| Ipsen Innovation | Unresolved — no canonical attribution shown | $471.88 | 1.4% | 2 | 2025 |
| Lundbeck LLC | Unresolved — no canonical attribution shown | $205.68 | 0.6% | 9 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $54.81 | 0.2% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $22.13 | 0.1% | 1 | 2025 |
| Tonix Medicines, Inc. | Unresolved — no canonical attribution shown | $16.14 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $15,187.50 | 6 |
| Consulting Fee | $13,412.50 | 6 |
| Food and Beverage | $1,989.57 | 74 |
| Honoraria | $1,925.00 | 1 |
| Travel and Lodging | $1,913.44 | 4 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| QULIPTA Normalized: qulipta |
Drug | ABBVIE INC. | $23,632.31 | 37 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $6,152.05 | 21 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $5,608.65 | 20 | 2025 |
Source payment records
|
|||||
| Symbravo Normalized: symbravo |
Drug | Axsome Therapeutics, Inc. | $2,065.69 | 3 | 2025 |
Source payment records
|
|||||
| BOTOX Normalized: botox |
Biological | ABBVIE INC. | $1,482.98 | 10 | 2025 |
Source payment records
|
|||||
| ZAVZPRET Normalized: zavzpret |
Drug | PFIZER INC. | $219.16 | 17 | 2025 |
Source payment records
|
|||||
| VYEPTI Normalized: vyepti |
Biological | Lundbeck LLC | $205.68 | 9 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $22.13 | 1 | 2025 |
Source payment records
|
|||||
| ZEMBRACE SYMTOUCH Normalized: zembrace symtouch |
Drug | Tonix Medicines, Inc. | $16.14 | 1 | 2025 |
Source payment records
|
|||||
| ABRYSVO Normalized: abrysvo |
Biological | PFIZER INC. | $4.45 | 2 | 2025 |
Source payment records
|
|||||
| COMIRNATY Normalized: comirnaty |
Biological | PFIZER INC. | $4.45 | 2 | 2025 |
Source payment records
|
|||||
| PREVNAR 20 Normalized: prevnar 20 |
Biological | PFIZER INC. | $4.45 | 2 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| BOTOX botox |
2025 | Botox | 2024 | 33 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| NURTEC ODT nurtec odt |
2025 | Nurtec Odt | 2024 | 24 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| QULIPTA qulipta |
2025 | Qulipta | 2024 | 38 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | BOTOX open payments reported associated product |
CMS Open Payments — General Payments 140321 supporting records · 30103 recipient NPIs · example record 1201352642 |
Botox · 2024 Exact normalized brand match · 1 Part D row |
33 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | QULIPTA open payments reported associated product |
CMS Open Payments — General Payments 298617 supporting records · 58957 recipient NPIs · example record 1201352530 |
Qulipta · 2024 Exact normalized brand match · 1 Part D row |
38 | suppressed by CMS |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
37 | suppressed by CMS |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Rybelsus open payments reported associated product |
CMS Open Payments — General Payments 161257 supporting records · 55409 recipient NPIs · example record 1188130076 |
Rybelsus · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
61 | 16 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | NURTEC ODT open payments reported associated product |
CMS Open Payments — General Payments 217574 supporting records · 54025 recipient NPIs · example record 1228794063 |
Nurtec Odt · 2024 Exact normalized brand match · 1 Part D row |
24 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 288 | 75 |
| Duloxetine Hcl | Duloxetine Hcl | 226 | 36 |
| Lisinopril | Lisinopril | 197 | 51 |
| Amlodipine Besylate | Amlodipine Besylate | 179 | 47 |
| Metoprolol Succinate | Metoprolol Succinate | 178 | 43 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 165 | 43 |
| Candesartan Cilexetil | Candesartan Cilexetil | 144 | 29 |
| Levothyroxine Sodium | Levothyroxine Sodium | 136 | 26 |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 130 | 24 |
| Topiramate | Topiramate | 122 | 22 |
| Hydrochlorothiazide | Hydrochlorothiazide | 106 | 27 |
| Omeprazole | Omeprazole | 102 | 26 |
| Chlorthalidone | Chlorthalidone | 98 | 21 |
| Carvedilol | Carvedilol | 97 | 19 |
| Metformin Hcl | Metformin Hcl | 86 | 26 |
| Pantoprazole Sodium | Pantoprazole Sodium | 85 | 23 |
| Pregabalin | Pregabalin | 83 | 15 |
| Aimovig Autoinjector | Erenumab-Aooe | 75 | 12 |
| Simvastatin | Simvastatin | 74 | 19 |
| Gabapentin | Gabapentin | 72 | 18 |
| Buspirone Hcl | Buspirone Hcl | 67 | 11 |
| Sumatriptan Succinate | Sumatriptan Succinate | 67 | 17 |
| Jardiance | Empagliflozin | 66 | 16 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 65 | 14 |
| Trazodone Hcl | Trazodone Hcl | 64 | 16 |
| Clonazepam | Clonazepam | 62 | suppressed |
| Escitalopram Oxalate | Escitalopram Oxalate | 62 | 12 |
| Irbesartan | Irbesartan | 62 | 16 |
| Tamsulosin Hcl | Tamsulosin Hcl | 62 | 14 |
| Zolpidem Tartrate | Zolpidem Tartrate | 62 | suppressed |
| Eliquis | Apixaban | 61 | 16 |
| Ropinirole Hcl | Ropinirole Hcl | 59 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 58 | 15 |
| Propranolol Hcl | Propranolol Hcl | 56 | 12 |
| Bupropion Xl | Bupropion Hcl | 54 | 13 |
| Farxiga | Dapagliflozin Propanediol | 53 | 11 |
| Potassium Chloride | Potassium Chloride | 50 | suppressed |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 48 | suppressed |
| Emgality Pen | Galcanezumab-Gnlm | 47 | suppressed |
| Furosemide | Furosemide | 45 | 13 |
| Famotidine | Famotidine | 41 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 38 | suppressed |
| Qulipta | Atogepant | 38 | suppressed |
| Ajovy Autoinjector | Fremanezumab-Vfrm | 37 | suppressed |
| Allopurinol | Allopurinol | 37 | 11 |
| Meloxicam | Meloxicam | 37 | 14 |
| Ozempic | Semaglutide | 37 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 36 | suppressed |
| Valsartan | Valsartan | 36 | suppressed |
| Prochlorperazine Maleate | Prochlorperazine Maleate | 35 | 12 |
| Botox | Onabotulinumtoxina | 33 | suppressed |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 32 | suppressed |
| Rizatriptan | Rizatriptan Benzoate | 31 | suppressed |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 30 | 12 |
| Fluticasone Propionate | Fluticasone Propionate | 30 | suppressed |
| Levetiracetam | Levetiracetam | 30 | suppressed |
| Trulicity | Dulaglutide | 30 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 29 | suppressed |
| Celecoxib | Celecoxib | 28 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 28 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 27 | suppressed |
| Donepezil Hcl | Donepezil Hcl | 27 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 27 | suppressed |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 27 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 26 | suppressed |
| Zonisamide | Zonisamide | 26 | suppressed |
| Dexamethasone | Dexamethasone | 25 | 19 |
| Losartan Potassium | Losartan Potassium | 24 | suppressed |
| Nurtec Odt | Rimegepant Sulfate | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Tramadol Hcl | Tramadol Hcl | 23 | suppressed |
| Mirtazapine | Mirtazapine | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 21 | suppressed |
| Diclofenac Potassium | Diclofenac Potassium | 21 | suppressed |
| Ondansetron Odt | Ondansetron | 21 | suppressed |
| Alprazolam | Alprazolam | 20 | suppressed |
| Montelukast Sodium | Montelukast Sodium | 20 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 19 | suppressed |
| Ibuprofen | Ibuprofen | 19 | suppressed |
| Shingrix | Varicella-Zoster Ge/As01b/Pf | 19 | 17 |
| Tolterodine Tartrate Er | Tolterodine Tartrate | 19 | suppressed |
| Aripiprazole | Aripiprazole | 18 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 18 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 18 | suppressed |
| Prednisone | Prednisone | 18 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 17 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 17 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 17 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 17 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 17 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 16 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 16 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 15 | suppressed |
| Bumetanide | Bumetanide | 15 | suppressed |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 15 | suppressed |
| Finasteride | Finasteride | 15 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 15 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 15 | suppressed |
| Mounjaro | Tirzepatide | 15 | suppressed |
| Atomoxetine Hcl | Atomoxetine Hcl | 14 | suppressed |
| Cephalexin | Cephalexin | 14 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 14 | suppressed |
| Linzess | Linaclotide | 14 | suppressed |
| Pioglitazone Hcl | Pioglitazone Hcl | 14 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 14 | suppressed |
| Synthroid | Levothyroxine Sodium | 14 | suppressed |
| Adacel Tdap | Diph,pertuss(Acell),tet Vac/Pf | 13 | 13 |
| Ultra-Fine Nano Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Atenolol | Atenolol | 12 | suppressed |
| Baclofen | Baclofen | 12 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 12 | suppressed |
| Hydromorphone Hcl | Hydromorphone Hcl | 12 | suppressed |
| Imipramine Hcl | Imipramine Hcl | 12 | suppressed |
| Nadolol | Nadolol | 12 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 12 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 11 | suppressed |
| Haloperidol | Haloperidol | 11 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 11 | suppressed |
| Lansoprazole | Lansoprazole | 11 | suppressed |
| Oxcarbazepine | Oxcarbazepine | 11 | suppressed |
| Rybelsus | Semaglutide | 11 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $34,428.01 · 91 records | ABBVIE INC. | ABRYSVO, BOTOX, COMIRNATY, FREESTYLE LIBRE 3, NURTEC ODT, PREVNAR 20, QULIPTA, Symbravo, UBRELVY, VYEPTI, ZAVZPRET, ZEMBRACE SYMTOUCH | 8 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Botox play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error